Biocon's Biosimilars IPO: Indian Pharma Giant Eyes March 2026 Listing

Indian biopharmaceutical powerhouse Biocon is gearing up to list its lucrative biosimilars business by March 2026. CEO Shreehas Tambe revealed plans to launch five new biosimilars in the U.S. market next fiscal year, aiming for double-digit market share. The company has been strategically preparing for this move, integrating its acquired biosimilars firm Viatris and refinancing debt. Biocon's biosimilars division, which contributes significantly to its revenue, is poised for expansion in both U.S. and European markets. This IPO marks a pivotal moment in Biocon's growth trajectory and the broader biosimilars industry.

Source: Reuters